Summary & Overview
CPT 4195F: Initiation of Disease Modifying Antirheumatic Therapy for Rheumatoid Arthritis
Headline: CPT code 4195F flags first-time DMARD prescriptions for rheumatoid arthritis
CPT code 4195F is used to indicate that a clinician has initiated a disease modifying antirheumatic drug (DMARD) therapy for a patient with rheumatoid arthritis. The code signals the start of disease-targeted pharmacologic management intended to reduce inflammation and slow disease progression. Nationally, tracking initiation of DMARDs is important for quality measurement, care coordination, and monitoring adherence to guideline-recommended treatment for inflammatory arthritis.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the code, typical service settings, and the types of benchmarks and policy topics commonly associated with DMARD initiation coding. The publication covers coding use cases, expected service lines (outpatient rheumatology and specialty care), and national implications for quality reporting and payer coverage policy.
This summary prepares clinicians, billing staff, and policy analysts to understand where CPT code 4195F fits within rheumatoid arthritis management workflows, what to expect from payer coverage and reporting, and which operational and policy issues are most relevant when this code is reported.
Billing Code Overview
CPT code 4195F reports that a provider prescribes a disease modifying antirheumatic drug (DMARD) therapy for the first time to a patient with rheumatoid arthritis. DMARDs are medications used to decrease pain and inflammation by suppressing the body’s overactive immune and inflammatory systems.
Service Type
- Service type: Initial prescription/initiation of disease modifying antirheumatic drug therapy
Typical Site of Service
- Typical site of service: Outpatient clinic or office-based rheumatology practice
Clinical & Coding Specifications
Clinical Context
A 52-year-old female with a 6-month history of progressive symmetric polyarthritis presents to a rheumatology clinic with persistent morning stiffness, elevated inflammatory markers, and imaging evidence of erosive changes. After confirming the diagnosis of rheumatoid arthritis and completing baseline screening (tuberculosis testing, hepatitis B and C serologies, complete blood count, liver function tests, and appropriate immunizations), the rheumatology provider initiates a disease-modifying antirheumatic drug (DMARD) as first-line pharmacologic therapy. The visit includes medication counseling, review of risks and benefits, documentation of baseline labs, and a prescription or in-office administration plan. Follow-up is arranged for monitoring therapeutic response and adverse effects, with orders placed for laboratory monitoring at appropriate intervals. Typical workflow steps: patient evaluation and diagnosis confirmation, baseline safety screening, shared decision-making and consent, documentation of DMARD prescription initiation (reported with 4195F), patient education, and scheduling of laboratory and clinical follow-up.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service on the same day | Use when a distinct E/M visit is performed in addition to DMARD prescribing |
| Distinct procedural service | Use to indicate a separate procedure unrelated to the DMARD initiation performed same day